Market Place
Sourcing Support
Teva Presents Schizophrenia Research, Phase 3 SOLARIS Trial Results
01 Nov 2024 //
GLOBENEWSWIRE
New Data On Switching Schizophrenia Patients To UZEDY
21 Sep 2024 //
GLOBENEWSWIRE
Ipca Labs Generic Risperidone Receives Approval in US
26 Jun 2024 //
FDA
Teva and MedinCell`s long-acting schizophrenia med wins in phase 3
09 May 2024 //
FIERECE PHARMA
New Pharmacokinetic Modeling Data Presented by Teva at SIRS 2024
06 Apr 2024 //
BUSINESSWIRE
Lyndra Announces Positive Data from Phase 3 Study with Oral Weekly Risperidone
04 Jan 2024 //
BUSINESSWIRE
UZEDY Injectable Suspension Significantly Prolongs Time to Schizophrenia
01 Nov 2023 //
BUSINESSWIRE
Teva to Present Data for AUSTEDO Extended-Release Tablets, AUSTEDO Tablets
06 Sep 2023 //
BUSINESSWIRE
FDA approves Teva, MedinCell`s long-acting schizophrenia therapy
02 May 2023 //
FIERCE PHARMA
Teva and MedinCell Announce FDA Approval of UZEDY Injectable Suspension
28 Apr 2023 //
BUSINESSWIRE
US FDA approves Luye Pharma’s schizophrenia treatment Rykindo
16 Jan 2023 //
PHARMACEUTICAL TECHNOLOGY
J&J Settles Most Risperdal Lawsuits, With $800 Million in Expenses
30 Oct 2021 //
USNEWS
Teva to Present New Data from Growing Mental Health Portfolio at Psych
21 Oct 2021 //
BUSINESSWIRE
Indivior Takes Strategic Alignment Actions
23 Sep 2020 //
BIOSPACE
China grants priority review to Luye Pharma`s schizophrenia drug
04 Jan 2020 //
BIOSPECTRUMASIA
J&J reels after FDA finds `sub-trace` levels of asbestos in its baby powder
19 Oct 2019 //
FIERCE PHARMA
J&J earnings beat expectations despite legal challenges from opioids and talc
16 Oct 2019 //
CNBC
Can J&J, on the litigation hot seat, hold off long-term brand?
14 Oct 2019 //
FIERCE PHARMA
J&J, besieged by lawsuits, could be a steal for investors: analyst
12 Oct 2019 //
FIERCE PHARMA
Jury smacks J&J with $8B Risperdal verdict, but will it stand up in appeals?
10 Oct 2019 //
FIERCE PHARMA
Johnson & Johnson Ordered To Pay $8 Billion In Male Breast Growth Case
09 Oct 2019 //
FORBES
Indivior signs deal to sell schizophrenia drug in Canada
10 May 2019 //
REUTERS
Luye Pharma`s Risperidone ER Reached Final Stage of NDA Process
01 Jan 2019 //
BIOSPACE
Indivior hit hard as generic Suboxone defence crumbles
22 Nov 2018 //
PHARMAPHORUM
Indivior’s once-monthly schizophrenia injection gets US green light
30 Jul 2018 //
PHARMAPHORUM
FDA Approves PERSERIS risperidone ER Injectable Suspension for Schizophrenia
30 Jul 2018 //
PR NEWSWIRE
DURECT Announces FDA Approval of Indivior PERSERIS (risperidone) ER Injectable
30 Jul 2018 //
PR NEWSWIRE
U.S. court expedites Indivior rival`s appeal to re-launch generic drug
30 Jul 2018 //
REUTERS
Luye Pharma receives China approval for CNS drug
23 Jul 2018 //
BIOSPECTRUM
The Lawsuits Keep Coming for Johnson & Johnson
11 Mar 2017 //
BLOOMBERG
Lawyers Investigate Invega Gynecomastia Lawsuits Against Janssen
18 Jan 2017 //
NEWSINFERNO
Bristol-Myers to pay $19.5 million in Abilify off-label marketing settlement
14 Dec 2016 //
FIERCE PHARMA
Risperdal Settlement Reached In Pennsylvania Gynecomastia Lawsuit
02 Nov 2016 //
THE LEGAL INTELLIGENCE
J&J Facing At Least 13,000 Product Liability Claims Over Atypical Antipsychotics
26 Oct 2016 //
PR NEWSWIRE
U.S. approves first drug for psychosis linked to Parkinson`s
30 Apr 2016 //
REUTERS
Kentucky reaches $39.5 million settlement with Purdue, Johnson & Johnson
24 Dec 2015 //
REUTERS
UPDATED: J&J slapped with $1.75M verdict in Risperdal breast growth case
11 Nov 2015 //
FIERCE PHARMA
New Study Warns of Side Effect Risk in “Off-label” Drug Prescribing
04 Nov 2015 //
NEWS INFERNO
HK-listed Luye shares gain as U.S. FDA NDA submission for LY03004 on track
09 Oct 2015 //
FIERCE PHARMA ASIA
Allergan and Richter`s antipsychotic gets FDA OK but faces stiff competition
19 Sep 2015 //
FIERCE PHARMA
Janssen Pharmaceuticals Accused of Hiding Risperdal`s Breast Effects In Boys
29 Aug 2015 //
FORBES
SC high court cuts J&J`s Risperdal marketing penalty back again, to $124M
09 Jul 2015 //
FIERCE PHARMA
Recall: APO-Risperidone (2015-06-03)
03 Jun 2015 //
HEALTHY CANADIANS
J&J nears $7.5M deal in Risperdal case that could have cost $1.2B
21 May 2015 //
FIERCE PHARMA
Jury: Boy Didn`t Prove J&J Drug Caused His Breast Growth
23 Mar 2015 //
FIERCE PHARMA
Psychiatric Drug Overuse Is Cited by Federal Study
01 Mar 2015 //
THE NEW YORK TIMES
SC`s Top Court Backs Risperdal Verdict against J&J, But Cuts Penalty to $136M
27 Feb 2015 //
FIERCE PHARMA
J&J Slams Ex-FDA Chief in Male Breast-Growth Case
04 Feb 2015 //
BLOOMBERG BUSINESS
J&J Again Faces Off-Label Marketing Claims in Risperdal Case of Boy Who Grew Breasts
26 Jan 2015 //
FIERCE PHARMA
